Other orally administered drugs and nutritional supplements in the gastrointestinal lumen

This target refers to the heterogeneous group of exogenous substances, including therapeutic medications and dietary supplements, present within the gastrointestinal (GI) tract that are subject to sequestration by non-absorbable binding agents (DrugBank DB09278). It is not a single biological molecule but rather a functional category representing the site of physical or chemical interactions in the GI lumen. Agents such as activated charcoal, bile acid sequestrants, and ion-exchange resins target these substances to prevent their systemic absorption, which is a critical strategy in treating acute poisonings and managing chronic conditions like hyperphosphatemia or hyperkalemia (StatPearls NBK482294). The primary pharmacological challenge associated with this "target" is the lack of specificity, as binding agents may inadvertently sequester essential co-administered drugs, leading to reduced bioavailability and therapeutic failure (PubMed PMID: 25835321). Consequently, clinical management often requires staggered dosing to minimize these significant drug-drug interactions (PubMed PMID: 29431068). These interactions occur through various mechanisms, including physical adsorption onto porous surfaces or ionic bonding to resin functional groups. Monitoring efficacy typically involves measuring the serum concentrations of the intended sequestered substance or observing clinical improvements in toxicity symptoms. Safety concerns primarily revolve around the potential for nutrient malabsorption and gastrointestinal side effects like constipation or obstruction.

Other names

Gastrointestinal luminal contentsCo-administered medicationsExogenous luminal solutesDietary supplementsLuminal drugs

Binding agents act via physical adsorption, chelation, or ion exchange to sequester substances within the gastrointestinal lumen, preventing their absorption into the systemic circulation (DrugBank DB09278; PubMed PMID: 25835321).